Table 4.

Outcomes with BFM regimen.

	Combined groups (n=29)	Augmented BFM (n=13)	Standard BFM (n=16)
Treatment tolerability
Completed full course of BFM†	15 (52%)	5 (38%)	10 (63%)
Discontinued BFM early (without relapse)	6 (21%)	3 (23%)	3 (19%)
Discontinued BFM early (with relapsed or refractory disease)	7 (24%)	5 (38%)	3 (19%)
Treatment-related mortality	2 (7%)	0 (0%)	2 (13%)
Responses to induction therapy‡
Refractory disease	1 (4%)	1 (8%)	0 (0%)
Complete remission	27 (93%)	12 (92%)	15 (94%)
Relapses
Relapsed disease	13 (45%)	6 (46%)	7 (44%)
Relapse during BFM	7 (24%)	4 (31%)	3 (19%)
Relapse after BFM	6 (21%)	2 (15%)	4 (25%)
CNS relapses*	2 (7%)	0 (0%)	2 (13%)

^†Includes patients completing all phases of BFM including ≥6 cycles of maintenance chemotherapy.

^‡One patient in the standard BFM group died from toxicity during induction and is considered a non-responder.

^*Nine of 13 relapses with documented lumbar punctures at relapse.